Ligand Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell LGND and other ETFs, options, and stocks.

About LGND

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. 

CEO
Todd Christopher Davis
CEOTodd Christopher Davis
Employees
47
Employees47
Headquarters
Jupiter, Florida
HeadquartersJupiter, Florida
Founded
1987
Founded1987
Employees
47
Employees47

LGND Key Statistics

Market cap
5.99B
Market cap5.99B
Price-Earnings ratio
141.01
Price-Earnings ratio141.01
Dividend yield
—
Dividend yield—
Average volume
257.29K
Average volume257.29K
High today
$324.00
High today$324.00
Low today
$297.63
Low today$297.63
Open price
$316.57
Open price$316.57
Volume
244.15K
Volume244.15K
52 Week high
$326.63
52 Week high$326.63
52 Week low
$175.89
52 Week low$175.89

Stock Snapshot

Ligand Pharmaceuticals(LGND) stock is priced at $299.00, giving the company a market capitalization of 5.99B. It carries a P/E multiple of 141.01.

As of 2026-11-05, Ligand Pharmaceuticals(LGND) stock has fluctuated between $297.63 and $324.00. The current price stands at $299.00, placing the stock +0.5% above today's low and -7.7% off the high.

The Ligand Pharmaceuticals(LGND)'s current trading volume is 244.15K, compared to an average daily volume of 257.29K.

In the last year, Ligand Pharmaceuticals(LGND) shares hit a 52-week high of $326.63 and a 52-week low of $175.89.

In the last year, Ligand Pharmaceuticals(LGND) shares hit a 52-week high of $326.63 and a 52-week low of $175.89.

LGND News

Simply Wall St 4d
Ligand Pharmaceuticals Raises EPS View As Royalty Growth Keeps Undervalued Narrative Alive

Advertisement Q3 2026 earnings reset the baseline Ligand Pharmaceuticals (LGND) gave investors a mixed picture in its latest update. Q3 2026 brought a net los...

Simply Wall St 6d
How Royalty Revenue Growth At Ligand Pharmaceuticals Has Changed Its Investment Story

Ligand Pharmaceuticals reported third quarter 2026 results with revenue of US$78.75 million and a net loss of US$28.49 million, while reaffirming full year reve...

Analyst ratings

100%

of 11 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own LGND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.